Interview: Diane Gosselin, President and CEO, CQDM, Canada
The president & CEO of CQDM discusses her vision of how CQDM’s activities can have a direct impact on the development of safer and more efficient drugs, and how to…
MissionCQDM is a not-for-profit organization whose mission is to identify, fund and support joint research projects between the academic and private biopharmaceutical sectors. Projects funded by CQDM target the development of innovative tools and technologies that accelerate the drug discovery process.
Objectives
CQDM is dedicated first and last to the stimulation of research in the field of therapeutic medicine and in particular to the development of innovative tools facilitating the discovery of safer and more effective compounds. By promoting synergy between academic and industrial research and by creating an international exchange network, CQDM intends to expand Quebec’s leadership in biopharmaceutical research and open new research avenues that will have a strong impact on the industry. CQDM activities also benefit small biotechnology companies. Its unique team approach favours access to internationally renowned experts. By leading research efforts towards market expectations, CQDM fully plays its role in disseminating knowledge and creating economic value.
Québec Consortium for Drug Discovery (CQDM)
7140, Albert-Einstein, suite 100
Montreal (Québec) Canada
H4S 2C1
Tel.: 514 766-6661
Fax: 514 766-9613
email: cqdm@cqdm.org
http://www.cqdm.org/en/index.php
The president & CEO of CQDM discusses her vision of how CQDM’s activities can have a direct impact on the development of safer and more efficient drugs, and how to…
World Courier’s national operations manager in Canada covers the topics of moving to GxP standards, and the logistics challenges faced by being a logistics company in such a…
Dr. Youssef Benanni, before becoming Site Head and VP of R&D, worked as a Sr. Group leader with Abbott before moving on to being Sr. Director of Medicinal Chemistry with…
Dr. Youssef Benanni, before becoming Site Head and VP of R&D, worked as a Sr. Group leader with Abbott before moving on to being Sr. Director of Medicinal Chemistry with…
Dr. Youssef Benanni, before becoming Site Head and VP of R&D, worked as a Sr. Group leader with Abbott before moving on to being Sr. Director of Medicinal Chemistry with…
Mr. Pierre Laurin is a senior executive with 28 years of experience in the pharmaceutical and biotechnology industry. Involved in the development of ProMetic’s platform technology since 1989, Mr. Laurin…
You have had a wealth of experience in the pharmaceutical industry with different positions in key therapeutic areas, ranging from Argentina, Latin America, Middle East & Africa, Algeria, Switzerland and France.…
You have been managing the Canadian affiliate of Shire since 2004. Could you briefly describe some of the key milestone achievements of this affiliate in the last few years? Shire…
You have been managing the Canadian affiliate of Shire since 2004. Could you briefly describe some of the key milestone achievements of this affiliate in the last few years? Shire…
You have been managing the Canadian affiliate of Shire since 2004. Could you briefly describe some of the key milestone achievements of this affiliate in the last few years? Shire…
With a Master’s Degree in Marketing Science from the University of Leicester and a Degree in Management Information Systems from Université du Québec à Montréal Jacques Dessurealt has had a…
Tell us about the Canada Foundation for Innovation (CFI) – where does Canada fit on the world stage of innovation and how are you ensuring Canada stands out as a…
Dr. Douville talks investment, the company’s role in R&D in Canada and their plans for some of their future products. You founded Milestone Pharmaceuticals in 2005, having founded Galileo Genomics…
See our Cookie Privacy Policy Here
